Global Cancer Biomarkers Market - Growth, Trends and Forecasts (2017 - 2022)

The global biomarkers market was worth USD $ 13.16 billion in 2011 and it is expected to reach USD 30.2 billion by 2019 at a CAGR of 14.60%.



Biomarkers are chemical, physical or biological parameters which can be used to indicate disease states. Oncology biomarkers offers high speed, non invasive cancer diagnosis and believe to enhance cancer detection and screening.



Major driving factors for the market are streamlined drug delivery process, noninvasive technology, increased rates of survival. Increase boost in government and private funding for oncology also fuels the market growth. Market is constrained by high cost of diagnosis, issues related to reimbursement and some of the regulatory policies which hinder the market growth. Government agencies such as Food and Drug Administration (FDA) and the National Cancer Institute (NCI) have taken an active interest in the field.



Global biomarkers market is segmented based on type of applications, By services and based on Geography. Global Cancer Biomarker market is segmented based on Cancer biomarker discovery market , and cancer biomarker diagnostic market. Among the different regions of the world, North America is recorded as the leading biomarker marker due to rapid growth of IT industry and high adoption of throughput technologies, for the discovery of biomarkers.



Some of the major players in this market are Abbott Laboratories,Correlogic Systems, Inc, Agendia Bv,Biocurex Inc,Astellas Pharma Us Inc, Beckman Coulter, Inc, Becton, Dickinson And Company, Biomerieux S.A., Biomoda, Inc, Clarient, Inc, Ambrilia Biopharma,Diadexus, Inc, Affymetrix, Inc and Aureon Laboratories, Inc. .



What makes our report Unique?



1) A wide and in depth analysis of various applications, and services provided in Global Biomarker market as well as cancer biomarker market.



2) We provide longest possible market segmentation based on the type of cancers, applications of biomarkers( Risk assessment, disease diagnosis, drug formulation, forensic application) Services( Sample preparation, Assay development, biomarkers validation and testing)



3) We provide you a complete competitive landscape which includes major players in the market, mergers and acquisitions, Collaborations and new product launches.

1. Introduction

1.1 Study Deliverables

1.2 Market Definition

1.3 Sizing Units

1.4 Base Currency

1.5 Review and Forecast Period Years

1.6 General Study Assumptions

2. Research Methodology

2.1 Introduction

2.2 Analysis Methodology

2.3 Econometric Forecast Model

2.4 Research Assumptions

3. Executive Summary

4. Key Inferences

5. Market Overview and Industry Trends

5.1 Current Market Scenario

5.2 Applications of Cancer Biomarkers

5.3 Technology Overview

5.4 New Developments

5.5 Industry Value-Chain Analysis

5.6 Product Life-Cycle Analysis

5.7 Product Benchmarking

5.8 Investment Analysis

5.9 Porter?s Five Forces

5.9.1 Bargaining Power of Suppliers

5.9.2 Bargaining Power of Consumers

5.9.3 Threat of New Entrants

5.9.4 Threat of Substitute Products and Services

5.9.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

7. Market Drivers

7.1 Non invasive technologies

7.2 Increased survival rates

7.3 Enhanced accuracy and Speed of diagnosis

7.4 Streamlined drug delivery process

7.5 Helps in FDA approval of drugs

7.6 Boost in government and Private funds for biomarkers discovery

8. Market Restraints

8.1 High cost of diagnosis

8.2 Reimbursement issues

8.3 Need for immediate processing

9. Key Challenges

9.1 Discovery of novel biomarkers

9.2 Regulatory and Reimbursement issues

9.3 Translational genetics

10. Current Opportunities in the Market

10.1 Genetics-based in-vitro diagnostics

10.2 Research and development

11. Market Segmentation

11.1 By Disease

11.1.1 Prostate cancer

11.1.2 Breast cancer

11.1.3 Lung cancer

11.1.4 Colorectal cancer

11.1.5 Cervical Cancer

11.1.6 Others

11.2 By Applications

11.2.1 Risk Assesment

11.2.2 Devlopment of molecular diagnostics

11.2.3 Disese diagnosis

11.2.4 Drug discovery and development

11.2.5 Drug formulation

11.3 By Services

11.3.1 Sample preparation

11.3.2 Assay developement

11.3.3 Biomakers validation and testing

11.4 By Type

11.4.1 Protein biomarkers

11.4.2 Genetic biomarkers

11.4.3 Others (Cell, Viral and Carbohydrate biomarkers)

11.5 By profiling technologies

11.5.1 Omics technologies

11.5.1.1 Genomics

11.5.1.2 Proteomics

11.5.1.3 Metabolomics

11.5.1.4 Transcriptomics

11.5.1.5 Pharmacogenomics

11.5.2 Imaging technologies

11.5.3 Immunoassays

11.5.3.1 Immunohistochemical (IHC) tests

11.5.3.2 Flow cytometry

11.5.4 Cytogenetics

11.5.4.1 DNA microarrays

11.5.5 Bioinformatics

11.5.6 IVD multivariate index assays

11.6 By Geography

11.6.1 North America

11.6.1.1 Introduction

11.6.1.2 US

11.6.1.3 Canada

11.6.1.4 Mexico

11.6.2 Europe

11.6.2.1 Introduction

11.6.2.2 France

11.6.2.3 UK

11.6.2.4 Germany

11.6.2.5 Russia

11.6.2.6 Italy

11.6.2.7 Spain & Portugal

11.6.2.8 Scandinavia

11.6.2.9 BENELUX

11.6.3 Asia-Pacific

11.6.3.1 Introduction

11.6.3.2 India

11.6.3.3 China

11.6.3.4 Japan

11.6.3.5 Australia & New Zealand

11.6.3.6 Soth Korea

11.6.4 Middle-East and North Africa (MENA)

11.6.4.1 Introduction

11.6.4.2 GCC

11.6.4.3 Egypt

11.6.4.4 Sudan

11.6.4.5 Morocco

11.6.5 South America

11.6.5.1 Introduction

11.6.5.2 Brazil

11.6.5.3 Argentina

11.6.5.4 Colombia

11.6.5.5 Chile

11.6.5.6 Peru

11.6.5.7 Venezuela

12. Competitive Landscape

12.1 Merger and Acquisition Analysis

12.2 New Product Launches

12.3 Agreements, Collaborations & Partnerships

13. 9. Company Profiles

13.1 Abbott Laboratories

13.2 Affymetrix Inc

13.3 Agilent Technologies

13.4 Gen-Probe Inc

13.5 Hologic Inc

13.6 Roche Diagnostics Corp.

13.7 23andMe

13.8 Ambry Genetics

13.9 Astex Pharmaceuticals

13.10 Atossa Genetics

13.11 BioMerieux

13.12 CuraGen

13.13 Celera Corporation (Quest Diagnostics)

13.14 Celldex Therapeutics

13.15 deCode Genetics (Amgen)

13.16 Foundation Medicine

13.17 Illumina

13.18 Genelex

14. Analyst Outlook for Investment Opportunities

15. Future Outlook of the Market

Content are not available

Choose License Type